{
      "Rank": 1,
      "Acronym": [
            "DCMII"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.",
            "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.",
            "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.",
            "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.",
            "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.",
            "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention."
      ],
      "ArmGroupInterventionName": [
            "Other: Placebo",
            "Biological: allogeneic human mesenchymal stem cells (hMSCs)",
            "Other: Placebo",
            "Biological: allogeneic human mesenchymal stem cells (hMSCs)",
            "Other: Placebo",
            "Biological: allogeneic human mesenchymal stem cells (hMSCs)"
      ],
      "ArmGroupLabel": [
            "Genotype A administered with placebo Group",
            "Genotype A administered with hMSC Group",
            "Genotype B administered with placebo Group",
            "Genotype B administered with hMSC Group",
            "Genotype C administered with placebo Group",
            "Genotype C administered with hMSC Group"
      ],
      "ArmGroupType": [
            "Placebo Comparator",
            "Experimental",
            "Placebo Comparator",
            "Experimental",
            "Placebo Comparator",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04476901"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy."
      ],
      "BriefTitle": [
            "Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy"
      ],
      "CentralContactEMail": [
            "Shelly.L.Sayre@uth.tmc.edu",
            "lvc25@med.miami.edu"
      ],
      "CentralContactName": [
            "Shelly L Sayre, MPH",
            "Lina Caceres"
      ],
      "CentralContactPhone": [
            "713-500-9529",
            "305-243-5399"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "FED",
            "OTHER"
      ],
      "CollaboratorName": [
            "United States Department of Defense",
            "The University of Texas Health Science Center, Houston"
      ],
      "CompletionDate": [
            "December 2024"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Non-ischemic Dilated Cardiomyopathy"
      ],
      "ConditionAncestorId": [
            "D000006331",
            "D000002318",
            "D000006332",
            "D000083083",
            "D000030342"
      ],
      "ConditionAncestorTerm": [
            "Heart Diseases",
            "Cardiovascular Diseases",
            "Cardiomegaly",
            "Laminopathies",
            "Genetic Diseases, Inborn"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC14",
            "All",
            "BC16",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Heart and Blood Diseases",
            "All Conditions",
            "Diseases and Abnormalities at or Before Birth",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Cardiomyopathy",
            "Dilated Cardiomyopathy",
            "Dilated Cardiomyopathy"
      ],
      "ConditionBrowseLeafId": [
            "M11306",
            "M4719",
            "M8571",
            "M8572",
            "M2393",
            "M22839",
            "T1876"
      ],
      "ConditionBrowseLeafName": [
            "Cardiomyopathies",
            "Cardiomyopathy, Dilated",
            "Heart Diseases",
            "Cardiomegaly",
            "Laminopathies",
            "Genetic Diseases, Inborn",
            "Dilated Cardiomyopathy"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000009202",
            "D000002311"
      ],
      "ConditionMeshTerm": [
            "Cardiomyopathies",
            "Cardiomyopathy, Dilated"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\nMen and women aged 18 to 80 years (inclusive) at the time of signing the informed consent form.\nDiagnosis of NIDCM with left ventricular ejection fraction \u226445%. Note: a left ventricular end diastolic diameter (LVEDD) \u2265 5.6cm in male subjects, an LVEDD of \u2265 5.4cm in female subjects, or left ventricular end diastolic volume index \u2265 125 mL/m2 (in either sex).\nAppropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. At a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical indication precluding use of one or both of these agents. Subjects must be on a stable regimen for at least 30 days prior to the procedure. Dose titration is allowed.\nBe a candidate for cardiac catheterization.\nBe willing to undergo DNA test.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nBe eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy\nClinical manifestation of coronary artery disease (CAD) (e.g., chest pain and concomitant clinical findings such as electrocardiogram changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac MRI suggestive of undiagnosed CAD or history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Be indicated for or require coronary artery revascularization\nDocumented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries\nValvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent\nAortic stenosis with valve area \u2264 1.5cm2\nCardiomyopathy due to acute Post-partum (within 6 months), Non-compaction, or Hypertrophic cardiomyopathy\nCardiomyopathy due to any known toxin (e.g amyloid, anthracycline)\nQTc interval > 550 ms on baseline electrocardiogram (ECG) (note: QTc interval is the interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle)\nAutomated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent\nHave an estimated baseline glomerular filtration rate below the clinical site's institutional cutoff\nA hematologic abnormality during baseline testing as evidenced by hemoglobin < 9 g/dl; hematocrit < 30%; absolute neutrophil count < 2,000 or total WBC count more than 2 times upper limit of normal; or platelet values < 100,000/ul\nHave liver dysfunction, as evidenced by enzymes Aspartate Transaminase Enzyme (AST) and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN\nHave a bleeding diathesis or coagulopathy (International Normalised Ratio (INR) > 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions\nBe a solid organ transplant recipient. This does not include prior cell based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.\nHave a history of organ or cell transplant rejection\nHave a clinical history of malignancy within the past 2 years (i.e., subjects with prior malignancy must be disease free for 2 years), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma\nDrug and/or alcohol abuse or dependence within the past 9 months\nBe serum positive for HIV, hepatitis B surface antigen, or viremic hepatitis C\nDocumented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or aortic aneurysm. (Refer to \"Guidance to the PI\" section with regards to LV thrombus, below)\nBlood glucose levels (HbA1c) >10%\nSevere radiographic contrast allergy\nKnown history of anaphylactic reaction to penicillin or streptomycin\nHypersensitivity to dimethyl sulfoxide (DMSO)\nNon-cardiac condition with life expectancy < 1 year\nAcute stroke or transient ischemic attack within 3 months of enrollment\nBe pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods\nPacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note: pacemaker-dependent candidates without an ICD are not excluded)\n\nPresence of a pacemaker and/or ICD generator with any of the following limitations/conditions:\n\nmanufactured before the year 2000\nleads implanted < 6 weeks prior to consent\nnon-transvenous epicardial or abandoned leads\nsubcutaneous ICDs\nleadless pacemakers\nA cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent\nOther MRI contraindications (e.g. subject body habitus incompatible with MRI)\nNeed for advanced heart failure therapy (e.g. IV inotropes)\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial\nAny other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up"
      ],
      "EnrollmentCount": [
            "136"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Genotype A administered with hMSC Group",
            "Genotype B administered with hMSC Group",
            "Genotype C administered with hMSC Group",
            "Genotype A administered with placebo Group",
            "Genotype B administered with placebo Group",
            "Genotype C administered with placebo Group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All",
            "ANeo"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals",
            "Antineoplastic Agents"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M85407",
            "M8814"
      ],
      "InterventionBrowseLeafName": [
            "Plasma-lyte 148",
            "Altretamine"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low"
      ],
      "InterventionDescription": [
            "allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs",
            "Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "allogeneic human mesenchymal stem cells (hMSCs)",
            "Placebo"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Allogeneic mesenchymal stem cells",
            "Bone marrow-derived mesenchymal stem cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "September 29, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "September 28, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Joshua M Hare"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Stanford",
            "Miami",
            "Louisville",
            "Houston"
      ],
      "LocationContactEMail": [
            "fouziak@stanford.edu",
            "ashwinil@stanford.edu",
            "lvc25@med.miami.edu",
            "jat243@med.miami.edu",
            "heidi.wilson@louisville.edu",
            "julie.caswell@louisville.edu",
            "npiece@texasheart.org",
            "SCarranza@texasheart.org"
      ],
      "LocationContactName": [
            "Fouzia Khan, MBBS",
            "Ashwini Narayana",
            "Phil Yang, MD",
            "Lina Caceres",
            "Jairo Tovar",
            "Josh Hare, MD",
            "Heidi Wilson",
            "Julie Caswell",
            "Roberto Bolli, MD",
            "Nichole Piece",
            "Sylvia Carranza",
            "Emerson Perin, MD, PhD"
      ],
      "LocationContactPhone": [
            "650-736-1410",
            "305-243-5399",
            "305-243-5399",
            "502-540-3721",
            "502-587-4177",
            "832-355-9173",
            "832-355-8524"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact",
            "Principal Investigator",
            "Contact",
            "Contact",
            "Principal Investigator",
            "Contact",
            "Contact",
            "Principal Investigator",
            "Contact",
            "Contact",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "Stanford University",
            "University of Miami Miller School of Medicine",
            "University of Louisville",
            "Texas Heart Institute"
      ],
      "LocationState": [
            "California",
            "Florida",
            "Kentucky",
            "Texas"
      ],
      "LocationStatus": [
            "Recruiting",
            "Recruiting",
            "Recruiting",
            "Recruiting"
      ],
      "LocationZip": [
            "94304",
            "33136",
            "40202",
            "77030"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase IIB Randomized, Placebo-Controlled, Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of Allogeneic-MSC Versus Placebo in Patients With Non- Ischemic Dilated Cardiomyopathy"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of Miami"
      ],
      "OrgStudyId": [
            "20200566"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "University of Miami"
      ],
      "OverallOfficialName": [
            "Joshua Hare, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2024"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)"
      ],
      "PrimaryOutcomeMeasure": [
            "Change in LVEF"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Baseline, 12 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "University of Miami"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Joshua M Hare"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Principal Investigator"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "CDMRP-PR191597",
            "20-02-134"
      ],
      "SecondaryIdDomain": [
            "US Department of Defense",
            "BRANY IRB"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "Other Grant/Funding Number",
            "Other Identifier"
      ],
      "SecondaryOutcomeDescription": [
            "Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI",
            "Change in regional ventricular strain as assessed via cardiac HARP MRI",
            "The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)",
            "Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI",
            "Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI",
            "Change in maximal oxygen consumption (peak VO2) as assessed via treadmill",
            "Change in exercise tolerance as assessed as the distance covered via the six-minute walk test",
            "Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.",
            "NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)",
            "Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).",
            "Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay",
            "Change in NT-proBNP as assessed via blooddraw",
            "Change in NT-proBNP as assessed via blooddraw",
            "Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician",
            "Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician"
      ],
      "SecondaryOutcomeMeasure": [
            "Change in global ventricular strain",
            "Change in left regional strain",
            "Left ventricular function concordance",
            "Change in LVEDVI",
            "Change in LVESVI",
            "Change in Maximal oxygen consumption (peak VO2)",
            "Change in Exercise tolerance",
            "Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score",
            "Change in New York Heart Association (NYHA) Class",
            "Percent change in flow mediated diameter",
            "Change in EPC-CFU",
            "Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)",
            "Change in cytokines",
            "Incidence of MACE",
            "Incidence of TE-SAEs"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Baseline, 12 months",
            "Baseline, 12 months",
            "12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "Baseline, 12 months",
            "12 months",
            "Day 30"
      ],
      "SeeAlsoLinkLabel": [
            "Cardiovascular Cell Therapy Research Network",
            "Information on stem cells from the National Institutes of Health",
            "DCM II Trial"
      ],
      "SeeAlsoLinkURL": [
            "https://www.cctrn.org",
            "https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/stem-cells",
            "http://www.dcmii.org"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 7, 2021"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "September 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "July 20, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "July 15, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "July 15, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}